Hematopoietic Stem Cell Culture Platform for Clonal Hematopoiesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for studying and addressing clonal hematopoiesis (CH) due to the inability to culture and expand hematopoietic stem cells (HSPCs) with genomic modifications ex vivo, limiting the identification of genes that promote or inhibit CH.
Innovation Solution
A platform is developed for culturing and expanding HSPCs with endothelial cells, allowing for the rapid recapitulation of CH phenotypes ex vivo and enabling the identification of genes that promote or inhibit CH, using a combination of genomic modifications, CRISPR/Cas9 technology, and specific agents to target histone 3, lysine 9 demethylases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If HSPCs with genomic modifications are cultured ex vivo, then CH phenotypes can be studied and genes promoting CH can be identified, but current culture methods are inadequate and cannot maintain HSPCs with genomic modifications
Solution Approach 1:
The patent introduces endothelial cells as an intermediary component to create a co-culture system. These endothelial cells provide necessary support signals and microenvironmental cues that enable HSPCs with genomic modifications to be maintained and expanded ex vivo, resolving the inability to culture these cells adequately.
Solution Approach 2:
The co-culture system serves multiple functions: it maintains HSPC viability, enables expansion of rare cell populations, preserves genomic modifications, and allows phenotypic assessment. This multi-functional platform addresses several limitations of traditional single-cell culture methods simultaneously.
2Productivity
If HSPCs are cultured rapidly ex vivo to recapitulate CH phenotypes, then study time is reduced from months to weeks, but culture conditions must be optimized to maintain cellular fidelity
Solution Approach 1:
The patent establishes optimized co-culture conditions and protocols in advance that pre-configure the cellular microenvironment. This preliminary optimization of culture parameters (media composition, cell ratios, incubation conditions) enables rapid expansion while maintaining phenotypic fidelity without requiring iterative adjustments during the culture process.
3Object-generated harmful factors
If agents targeting H3K9 demethylases are used to inhibit CH, then CH progression can be blocked, but specific inhibitors must be identified through systematic screening
Solution Approach 1:
The patent extracts and isolates the specific molecular target (H3K9 demethylases) from the complex CH pathway. By identifying and targeting this specific enzymatic activity, the invention simplifies the therapeutic approach while maintaining efficacy, allowing focused screening for inhibitors rather than broad, unsystematic searches.
Data Source
AI summary
The present disclosure provides, in some embodiments, methods for culturing and expanding hematopoietic stem cells (HSPCs) comprising a genomic modification associated with clonal hematopoiesis (CH). These cultured and expanded HSPCs are used, in some embodiments, to identify genes that promote CH, to identify inhibitors of CH, and to inhibit CH.